Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Free Cash Flow (2016 - 2025)

vTv Therapeutics (VTVT) has disclosed Free Cash Flow for 12 consecutive years, with -$9.3 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 91.73% to -$9.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$25.3 million through Dec 2025, changed 0.21% year-over-year, with the annual reading at -$25.3 million for FY2025, 0.21% changed from the prior year.
  • Free Cash Flow hit -$9.3 million in Q4 2025 for vTv Therapeutics, down from -$5.2 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $706000.0 in Q2 2022 to a low of -$9.3 million in Q4 2025.
  • Historically, Free Cash Flow has averaged -$5.2 million across 5 years, with a median of -$5.3 million in 2021.
  • Biggest five-year swings in Free Cash Flow: skyrocketed 117.66% in 2022 and later crashed 973.51% in 2023.
  • Year by year, Free Cash Flow stood at -$6.4 million in 2021, then dropped by 7.22% to -$6.9 million in 2022, then soared by 57.65% to -$2.9 million in 2023, then tumbled by 65.58% to -$4.8 million in 2024, then tumbled by 91.73% to -$9.3 million in 2025.
  • Business Quant data shows Free Cash Flow for VTVT at -$9.3 million in Q4 2025, -$5.2 million in Q3 2025, and -$5.1 million in Q2 2025.